HCPLive

'Doctor Shoppers' Account for Less Than 2 Percent of All Opioid Prescriptions

THURSDAY, July 18 (HealthDay News) -- A small proportion of opioid prescription purchasers (0.7 percent) obtain an average of 32 prescriptions from 10 different prescribers, accounting for 1.9 percent of all opioid prescriptions, according to a study published online July 17 in PLOS ONE.

Douglas C. McDonald, PhD, and Kenneth E. Carlson, from Abt Associates Inc. in Cambridge, MA, examined the prevalence of doctor shopping to obtain multiple opioid prescriptions and the amounts and types of opioids involved. Records were reviewed for 146.1 million opioid prescriptions dispensed by 76 percent of U.S. retail pharmacies during 2008. Prescriptions were linked to unique patients.

The researchers found that patients in the extreme outlying population (0.7 percent of purchasers), who were thought to be doctor shoppers, obtained 32 prescriptions for opioids from 10 different prescribers, on average. This group purchased 1.9 percent of all opioid prescriptions, constituting 4 percent of the total weighed amounts that were dispensed.

"To close the information gap that makes doctor shopping and uncoordinated care possible, states have created prescription drug monitoring programs to collect records of scheduled drugs dispensed, but the majority of physicians do not access this information," the authors write. "To facilitate use by busy practitioners, most monitoring programs should improve access and response time, scan prescription data to flag suspicious purchasing patterns, and alert physicians and pharmacists."

The authors are employees of Abt Associates Inc., a commercial scientific research company.

Full Text

Copyright © 2013 HealthDay. All rights reserved.

Most Popular

Recommended Reading

Video Interview: Vinood Patel, PhD, PGCHE, fHEA, FRSC, University of Westminster, London, UK, shared valuable insight regarding chronic alcoholic demographics and biomarkers on the horizon at The International Liver Congress 2015.
The use of interferon to treat hepatitis C infections has fallen out of favor with the advent of new antivirals and drug combinations that have fewer side effects. But in a study presented at the 2015 International Liver Congress in Vienna, Austria, researchers from the UK said that physicians should put interferon back on the treatment menu.
In this video interview, Camille Barrault, MD, spoke about the implications her work with baclofen could have for the future of liver disease research at The International Liver Congress 2015, Vienna, Austria.
When it comes to developing heart disease, patients who have non-alcoholic steatohepatitis (NASH) liver disease are at greater risk of both cardiovascular illness and death than patients with non-alcoholic fatty liver disease a UK team reported today at the International Liver Congress in Vienna, Austria.
$vAR$